ANX - Sector: Healthcare---Industry: Biotechnology & Drugs

[saffeysite1]

If I see three big red candles with high sustaining volume = not good for stock.  If I get low volume with small red candles staying within the 20/9 ema.  I know its pullback, forming a base.  Positioning itself for the next leg up.

The best thing I have done is study great charts of stocks that went on to be huge winners throught stock history.  THere's a great book by O'neill "Finding winning stocks".  It has tons of examples of patterns of stocks that went on to become historic winners.

Hope that answers your question.

[phabrux]

Hello Saffey,

Thanks for the O'Neill book recommendation!
As a expert in Biotech, what do you think about PPHM stock?

Regards

[saffeysite1]

I have owned it before and took a loss on it some months ago.  MGMT knows how to really burn cash.   DOn't know if they raised more capitol for their drug pipline, but look up thier Debt/Cash ratio.  IF it's greater than 100.  I would Stay out for now.

[eliteG]

I have a feeling this is ready to rock anyday...woohoo 

[Ramsburg]

I've bough some ANX today, near the closing bell

It's trading inside a short term ascending channel... I'll post here the chart later.

Applaud again saffey

[saffeysite1]

Price and volume.  Not much to it.  Esp, when the stock is making new highs.  %20 retractment.

If a stock is coming off of bottom and starting to begin a new uptrend.   Then starts to pull back the next day, Their is no pullback there.  I sell.

Study current winning charts.  Exp.SWB, FC, TGE, BOOM, GOOGLE. 

[setravis]

Let's rock n roll!!!!!
I have the story on this pick......Top Secret....Tell me to buy!!!!!
Ready for tomorrow.......

[Ramsburg]

Ok guys...

Nobody can't argue with me that this chart is ON FIRE !!!!

Because I actually see some fire on it   

[setravis]

Okay,I'm in...today.So, let it rip potato chip.

[eliteG]

some TA:

[eliteG]

ANX released second quarter results this morning:

To me with some familiarity on bio-tech earnings it looks good.  Looks like a company going through the motions of bringing its pipeline to the market very efficiently(good job management).


http://biz.yahoo.com/bw/050812/125093.html?.v=1

SAN DIEGO--(BUSINESS WIRE)--Aug. 12, 2005--ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX - News) today announced financial results for the three and six months ended June 30, 2005.

ADVENTRX reported a net loss of $3.3 million, or $0.06 per share, for the second quarter of 2005, compared with a net loss of $1.5 million, or $0.03 per share, for the second quarter of 2004.

"In past several months, we have moved significantly closer to our corporate goal of introducing new anticancer and antiviral treatments that improve the performance and safety of existing drugs," said Evan M. Levine, ADVENTRX president and chief executive officer. "With our lead drug candidate CoFactor(TM), we have reported favorable clinical results that further confirm this drug candidate as a viable replacement for leucovorin to improve 5-fluorouracil (5-FU) effectiveness while lowering toxicity. Additionally, we have initiated a Phase IIb trial and received clearance from the US Food and Drug Administration (FDA) to begin a pivotal Phase III trial with CoFactor in metastatic colorectal cancer patients. Further, our preclinical work with Thiovir(TM) indicates that this orally administered, broad spectrum antiviral drug candidate shows potential promise as a more convenient, less toxic alternative to foscarnet for the treatment of opportunistic infections in HIV patients.

"With the completion of our $20 million financing, we are well situated financially to move forward with our aggressive clinical development plans with CoFactor and further capitalize on our drug development pipeline opportunities," added Mr. Levine.

Second Quarter and First Half of 2005 Financial Review

Research and development expenses for the second quarter of 2005 were $2.2 million, versus $773,000 for the second quarter of 2004. The increase for the 2005 second quarter was related primarily to expenses associated with the Company's clinical trials with CoFactor. General and administrative expenses for the 2005 second quarter were $1.1 million, compared with $746,000 for the same period in 2004. This increase was due primarily to the hiring of additional personnel in the finance and marketing, and business development departments; increased directors and officers insurance premiums; increased legal fees; and increased expenses associated with business development activities.

For the six months ended June 30, 2005, net loss was $6.2 million, or $0.11 per share, compared with a net loss of $2.2 million, or $0.05 per share, for the same period in 2004.

For the first six months of 2005, research and development expenses were $3.9 million, compared with $1.1 million first six months of 2004. General and administrative expenses for the first half of 2005 were $2.3 million, compared with $1.2 million for the same period in 2004.

The Company reported that it expects research and development expenses to significantly increase from levels reported in the 2005 second quarter as it ramps up for a pivotal Phase III CoFactor clinical trial and continues patient enrollment in its Phase IIb CoFactor clinical trial. The timing of the increase in research and development expenses is directly related to the timing of the launch of the Phase III trial, and the amount of increase will be directly related to the success and speed in patient enrollment in these trials. The Company also expects that general and administrative expenses will increase measurably during the remainder of 2005 as it prepares for compliance with Section 404 of the Sarbanes-Oxley Act.

ADVENTRX reported cash and cash equivalents of approximately $8.1 million as of June 30, 2005, compared with $13.0 million as of December 31, 2004. In July, the Company announced the completion of a $20 million private placement of the Company's common stock and warrants. Funds from this transaction will be reflected on the Company's balance sheet in the third quarter ending September 30, 2005.

About ADVENTRX

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments that improve the performance and safety of existing drugs by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance. The Company's lead compound, CoFactor, is a biomodulator of 5-FU, a widely used cancer chemotherapy. CoFactor met the primary endpoint for response and secondary endpoint for safety in an ongoing Phase II clinical trial. CoFactor is currently being tested with 5-FU in this US-based Phase II clinical trial and an EU-based Phase IIb clinical trial as a first line treatment of metastatic colorectal cancer. In addition, CoFactor has received clearance under a special protocol assessment from the US FDA to begin a Phase III pivotal clinical trial for metastatic colorectal cancer. More information can be found on the Company's Web site at www.adventrx.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the FDA and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's last quarterly report on Form 10-Q, as well as other reports that the Company files from time to time with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof.

            ADVENTRX PHARMACEUTICALS, INC. AND SUBSIDIARY
                   (A Development Stage Enterprise)
           Condensed Consolidated Statements of Operations
                             (unaudited)

                       Three months ended         Six months ended
                            June 30,                  June 30,
                    ------------------------  ------------------------
                       2005         2004         2005         2004
                    -----------  -----------  -----------  -----------

Net sales          $        --  $        --  $        --  $        --
Cost of goods sold          --           --           --           --
                    -----------  -----------  -----------  -----------
  Gross margin              --           --           --           --
Grant revenue               --           --           --           --
Interest income         64,597       13,341      101,919       16,687
                    -----------  -----------  -----------  -----------
                        64,597       13,341      101,919       16,687
                    -----------  -----------  -----------  -----------

Operating expenses:
Research and
  development        2,236,609      773,091    3,941,406    1,069,466
General and
  administrative     1,123,577      745,838    2,273,910    1,160,220
Depreciation and
  amortization          34,965        3,666       62,091        6,718
Impairment loss -
  write off of
  goodwill                  --           --           --           --
Interest expense           --           --           --           --
Equity in loss of
  investee                  --           --           --           --
                    -----------  -----------  -----------  -----------
  Total operating
   expenses          3,395,151    1,522,595    6,277,407    2,236,404
                    -----------  -----------  -----------  -----------
  Loss before
   cumulative effect
   of change in
   accounting
   principle        (3,330,554)  (1,509,254)  (6,175,488)  (2,219,717)
Cumulative effect
of change in
accounting
principle                  --           --           --           --
                    -----------  -----------  -----------  -----------
  Net loss          (3,330,554)  (1,509,254)  (6,175,488)  (2,219,717)
  Preferred stock
   dividends                --           --           --           --
                    -----------  -----------  -----------  -----------
  Net loss
   applicable to
   common stock    $(3,330,554) $(1,509,254) $(6,175,488) $(2,219,717)
                    ===========  ===========  ===========  ===========
  Loss per common
   share - basic
   and diluted     $      (.06) $      (.03) $      (.11) $      (.05)
                    ===========  ===========  ===========  ===========


            ADVENTRX PHARMACEUTICALS, INC. AND SUBSIDIARY
                   (A Development Stage Enterprise)
                Condensed Consolidated Balance Sheets

                                         June 30,        December 31,
                                           2005             2004
                                       -------------    --------------
                                        (unaudited)
               Assets

Current assets:
Cash and cash equivalents            $   8,102,824    $   13,032,263
Accrued interest income                         --            10,808
Prepaid expenses                           471,335           115,144
Other current assets                         3,138                --
Assets available for sale                       --           108,000
                                       -------------    --------------
     Total current assets                 8,577,297        13,266,215
                                       -------------    --------------
Property and equipment, net                 342,036           285,304
Other assets                                 58,387            57,268
                                       -------------    --------------
     Total assets                     $   8,977,720    $   13,608,787
                                       =============    ==============

Liabilities and Shareholders' Equity

Current liabilities:
Accounts payable                     $     270,779    $      532,327
Accrued liabilities                        770,612           628,753
Accrued salary and related taxes           126,364            57,315
                                       -------------    --------------
     Total current liabilities            1,167,755         1,218,396

Commitments and contingencies                    --                --
Shareholders' equity:
Common stock, $0.001 par value.
  Authorized 100,000,000 shares; issued
  55,046,086 shares in 2005 and
  53,834,237 shares in 2004                  55,047            53,835
Additional paid-in capital              49,147,347        47,553,497
Deficit accumulated during the
  development stage                     (41,357,682)      (35,182,194)
Treasury stock, 23,165 shares at cost      (34,747)          (34,747)
                                       -------------    --------------
     Total shareholders' equity           7,809,965        12,390,391
                                       -------------    --------------
     Total liabilities and
      shareholders' equity            $   8,977,720    $   13,608,787
                                       =============    ==============


Contact:

     ADVENTRX Pharmaceuticals
     Andrea Lynn, 858-552-0866
     or
     Investor Contact:
     Lippert/Heilshorn & Associates
     Jody Cain ([email protected])
     Brandi Floberg ([email protected])
     310-691-7100


Source: ADVENTRX Pharmaceuticals, Inc.

[stocky]

Is everyone still bullish on ANX?

Looking to start postion and would welcome any input.

[eliteG]

I would like to see 3.30 hold but 3.19 is also there.  Here is a support study I am doing.  Market is down heavy today.. so ANX is just doing what most other stocks are doing.  The bullish side of things are still there.  I will give it till Monday at least 

[KCScott]

I'm in at 3.48 with stop at 3.17

Down to 3.35 right now on an average looking volume day.

I think the 'earnings crowd may have cut bait - JMO

[stocky]

thx elite and kc. I am holding this baby for atleast three more days. There will be some shakeout and I am staying.